Table 3.
Patients with CA125 response or stabilization
|
Pt. |
Age |
Prior chemo regimens |
Response latest treatment |
Interval since latest treatment |
CA125 at study entry (U/mL) |
CA125 baseline for response (U/mL) |
CA125 nadir (U/mL) |
CA125 response (duration) |
CT scan response |
On study |
|---|---|---|---|---|---|---|---|---|---|---|
| (study day) | (study day) | |||||||||
|
Confirmed | ||||||||||
| 202 |
76 |
4 |
PD |
28 wks |
507 |
507 |
379 |
Stable 23 wks |
Target lesions stable at 24 weeks but new non-measurable lymphadenopathy |
23 wks |
| (d1) |
(d91) |
|||||||||
| 208 |
58 |
1 |
PR |
56 wks |
4939 |
4939 |
2326 |
Minor 10 wks |
Non-measurable disease only (ascites). New pleural effusion at 28 weeks |
34 wks |
| (d1) |
(d161) |
Stable 32 wks |
||||||||
| 219 |
48 |
1 |
CR |
54 wks |
214 |
408 |
189 |
Major 10 wks |
No abnormality on baseline or follow up scans |
68 wks |
| (d55) |
(d163) |
Stable 57 wks |
||||||||
| 228 |
62 |
3 plus immuno-therapy |
PD |
16 wks |
1455 |
2215 |
98 |
Major 71 wks |
32% increase in measurable disease at 12 weeks, reduced to 24% at 28 weeks and 21% at 42 weeks |
80 wks |
| (d33) |
(d161) |
|||||||||
|
Unconfirmed | ||||||||||
| 220 |
54 |
3 |
PR |
20 wks |
593 |
2442 |
1387 |
Minor 7 wks |
At 14 weeks target lesions stable but new ascites |
21 wks |
| (d55) | (d90) | Stable 11 wks | ||||||||